On August 26, 2020 Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, reported that it will be holding a conference call on September 2, 2020, at 4:30 p.m. ET, to highlight the planned commercial launch of DecisionDx-SCC, its prognostic gene expression profile test for patients diagnosed with high-risk cutaneous squamous cell carcinoma (SCC) (Press release, Castle Biosciences, AUG 26, 2020, View Source [SID1234564064]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The webcast will include Dr. Ashley Wysong, M.D., from the University of Nebraska Medical Center, as a guest speaker. There will be a brief Question & Answer session following management commentary.
Conference call and webcast details can be found below:
Title:
Castle Biosciences Decision Dx-SCC Launch
Date:
September 2, 2020
Time:
4:30 p.m. ET
Dial-in:
US/Canada Participant Toll-Free Dial-in number: (877) 282-2581
US/Canada Participant International Dial-in number: (470) 495-9479
Conference ID:
4576527
A live webcast of the conference call can be accessed here: View Source or via the webcast link on the Investor Relations page of the Company’s website (www.castlebiosciences.com). Please access the webcast at least 10 minutes before the conference call start time. An archive of the webcast will be available on the Company’s website until September 23, 2020.
About Cutaneous Squamous Cell Carcinoma
Cutaneous squamous cell carcinoma (SCC) is one of the most common cancers. Approximately 1 million patients are diagnosed with SCC each year in the U.S. While the majority of these patients have a favorable prognosis, approximately 200,000 of these patients are identified as high risk. National guidelines for high-risk patients provide for broad, aggressive treatment plan recommendations relative to low-risk patients. Traditional clinicopathologic based risk-factor staging systems suffer from low positive predictive value, meaning many more patients are classified as high risk than actually develop metastatic disease. This may lead to over- and under-treatment of a substantial number of cutaneous SCC patients. To address this clinical need, Castle Biosciences has developed a gene expression profile test designed to improve upon current staging systems and identify patients with cutaneous SCC at high risk for metastasis, in order to enable more informed, objective clinical decisions regarding adjuvant therapy and other management options.